Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Mortality Median · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Progression/relapse · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS) sensitivity analysis ‐ without HD6trial due to high risk of other bias
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS)… (moderate certainty).
1 finding from 1 review
HR 0.24 [0.07, 0.88]
900 participants
Moderate
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Second cancer‐ related mortality
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiac disease‐ related mortality
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Complete response rate
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS)
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS) (moderate certainty).
1 finding from 1 review
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Second cancer‐ related mortality
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiac disease‐ related mortality
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Complete response rate
The intervention showed no clear difference in complete response rate (low certainty).
1 finding from 1 review